BPC-157 Sexual Function Impact: What the Current Evidence Actually Shows

Does BPC-157 improve sexual function?

None of the human studies described by FDA or by the 2026 systematic review measured a sexual outcome. That review searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov through June 1, 2026 and included three eligible human studies with 30 patients in total, all judged poor methodological quality with certainty of evidence rated very low [1]. Those three tracked knee pain, bladder symptoms and intravenous tolerability [2][3][4].

FDA's own review identified five small human studies — meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot — and found no human study of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [5].

Animal research often cited for BPC-157

Reviews of BPC-157 describe animal findings involving blood vessels and neurotransmitter systems [8][9]. A 2018 review in Current Pharmaceutical Design describes BPC 157 as protecting the endothelium, preventing and reversing thrombosis in an anastomosed abdominal aorta, and counteracting the effect of L-NAME and/or L-arginine [8]. A 2016 review in Current Neuropharmacology states that BPC 157 "modulates serotonergic and dopaminergic systems", changed serotonin release in nigrostriatal brain areas when given peripherally, and beneficially affected behavioural disturbances linked to stimulated or damaged neurotransmitter systems [9]. The abstracts of both reviews do not mention sexual function.

Two limits apply. FDA noted that the protective effects reported for BPC-157 come from rat studies rather than human trials, that dose-response relationships were not established, and that the peptide's molecular targets have not been identified [5]. An animal vessel or behaviour result therefore does not establish what the peptide does in people.

What the human studies actually measured

• Knee pain: a retrospective chart review at one Florida clinic. Of 17 patients, 16 were reached by phone and 12 received BPC-157 alone into the knee; 11 of those 12 reported significant improvement. There was no control group and no validated outcome tool [2].
• Interstitial cystitis: 12 women received a total of 10 mg injected around the bladder wall in a single procedure; 10 of 12 reported complete symptom resolution and 2 reported about 80%. Single arm, patient-rated [3].
• Intravenous tolerability: 2 adults received 10 mg on day one and 20 mg on day two, with no measurable change in the heart, liver, kidney, thyroid or glucose markers tested and no side effects reported. Two people cannot establish safety [4][1].

The doses used in the human reports were: rectal enema up to 2 mg/kg daily for 8 days in healthy volunteers, 80 mg daily for 2 weeks in ulcerative colitis, 2 to 4 mg injected into the knee once or twice, 10 mg into the bladder wall once, and 10 mg then 20 mg intravenously on two days [5]. None is a recommended dose, and there is no FDA-approved dose [5]. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use; after rectal enemas the peptide was mostly not detectable in blood [5].

What is known about safety

BPC-157 is not an FDA-approved drug, and FDA says there is insufficient clinical safety information to characterize its safety profile [5]. FDA searched its adverse-event database through December 4, 2025 and found three reports, all injectable: injection-site redness and swelling for nine days (the patient also used a compounded thymosin), shortness of breath leading to an emergency department visit, and widespread darkening of skin and gums that returned on re-exposure to a BPC-157 plus TB-500 "research" product. FDA said it cannot tell whether BPC-157 caused any of them [5].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information; in the healthy-volunteer enema abstracts the most frequent events were headache and flatulence [5]. In animals, 28-day intramuscular studies showed shortened clotting time (aPTT) in rats but prolonged aPTT in dogs, plus raised ALT, glucose and triglyceride levels; longer studies and cancer-risk studies were not available [5].

Regulatory status in the US

BPC-157 is not an FDA-approved drug, has no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [5]. It sat in FDA's category 2 group for substances that may present significant safety risks from September 2023 until April 22, 2026, then moved to a "nominated but withdrawn" table after the nominating groups withdrew; removal was not a finding of safety [6][10]. It is not in category 1 either, so FDA's category 1 enforcement-discretion policy does not cover it [11].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation [12][10]. The vote is advice only, BPC-157 is not on the list, and adding it requires formal rulemaking [12][10]. FDA's own reviewers had proposed that it not be added, citing poor chemical characterization, limited information on safety and immunogenicity, insufficient evidence for ulcerative colitis, and approved drugs already available for that condition [5].

On October 28, 2026, HHS filed notice of a draft policy stating that it "does not intend to take enforcement action" against state-licensed pharmacies, federal facilities or licensed physicians that compound six named peptides, BPC-157 among them, if conditions are met — BPC-157 acetate only, subcutaneous, intramuscular, oral or topical forms, a single active ingredient, and a patient-specific prescription [13][10]. The notice says the policy establishes no rights and is not binding on HHS or the public, and that it may be revisited [13]. It names pharmacies, federal facilities and physicians rather than outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities [10][14]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [13][14]. WADA separately names BPC-157 in S0, prohibited at all times in and out of competition [7].

Bottom line

The idea that BPC-157 could affect sexual function rests on animal vascular and neurotransmitter studies [8][9], and how the peptide works in humans has not been identified [5]. FDA found the clinical safety information insufficient to characterize the drug's safety profile [5].